Impact of 13-Valent Pneumococcal Conjugate Vaccine on Meningitis and Pneumonia Hospitalizations in Children aged <5 Years in Senegal, 2010–2016

Abstract Background Senegal introduced a 13-valent pneumococcal conjugate vaccine (PCV13) in October 2013, given at 6, 10, and 14 weeks of age. We document trends of meningitis and pneumonia after the PCV13 introduction. Methods From October 2010–October 2016, hospitalization data for clinical menin...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2019-09, Vol.69 (Supplement_2), p.S66-S71
Main Authors: Faye, Papa M, Sonko, Mouhamadou A, Diop, Amadou, Thiongane, Aliou, Ba, Idrissa D, Spiller, Michael, Ndiaye, Ousmane, Dieye, Baidy, Mwenda, Jason M, Sow, Ahmed I, Diop, Boly, Diallo, Aliou, Farrar, Jennifer L
Format: Article
Language:English
Subjects:
Child, Preschool
Hospitalization - statistics & numerical data
Hospitals, Pediatric - statistics & numerical data
Humans
Infant
Meningitis, Bacterial - epidemiology
Meningitis, Bacterial - prevention & control
Pneumococcal Vaccines - administration & dosage
Pneumonia, Pneumococcal - epidemiology
Pneumonia, Pneumococcal - prevention & control
Registries
Senegal - epidemiology
Vaccines, Conjugate - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Senegal introduced a 13-valent pneumococcal conjugate vaccine (PCV13) in October 2013, given at 6, 10, and 14 weeks of age. We document trends of meningitis and pneumonia after the PCV13 introduction. Methods From October 2010–October 2016, hospitalization data for clinical meningitis and pneumonia in children aged
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciz457